1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class A

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class A

12.62
CNY
-0.24
(-1.87%)
8.74BMarket Cap
Oct 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.32
0.39
0.51
0.6
0.87
1.44
2.46
2.71
3.2
3.12
3.15
2.1
2.74
- -
Basic EPS, GAAP
0.09
0.11
0.11
0.18
0.2
0.31
0.68
0.82
0.93
0.8
0.72
0.33
0.71
- -
Free Cash Flow per Basic Share
0.06
0.04
-0.08
0.16
0.23
0.16
0.28
0.68
-0.1
0.04
1.25
-0.13
- -
- -
Dividend per Share
0.06
0.03
0.02
0.02
0.03
0.05
0.16
0.03
- -
0.13
0.31
0.44
0.05
- -
Book Value per Share
0.52
0.6
1.22
1.39
1.56
1.82
2.33
3.12
6.42
7.08
7.5
7.37
7.81
7.81
Tangible Book Value per Share
0.42
0.49
1.13
1.29
1.46
1.72
2.03
2.83
6.08
6.72
7.11
7.04
7.5
7.5
Basic Weighted Avg Shares
346
346
346
346
346
346
348
346
347
385
384
384
382
382
Sales/Revenue/Turnover
111
135
177
208
300
498
855
938
1,108
1,202
1,209
806
1,046
- -
Operating Margin (%)
35.07
32.68
22.29
35.25
26.98
23.45
33.18
35.71
34.76
27.69
24.24
16.37
30.86
- -
Depreciation Expense
2
4
5
6
2
2
2
3
3
9
10
9
11
- -
Net Income, GAAP
33
37
38
63
68
106
237
283
322
308
278
125
273
- -
Effective Tax Rate (%)
14.3
13.71
12.94
13.97
13.34
11.56
13.27
14.09
12.25
8.66
9.18
5.27
9.64
- -
Profit Margin (%)
29.55
27.53
21.35
30.51
22.74
21.22
27.68
30.22
29.09
25.61
22.99
15.51
26.06
- -
Working Capital
118
136
342
397
453
489
624
883
2,008
2,183
2,329
2,294
2,433
2,433
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
- -
1
1
- -
1
1
Total Equity
180
206
424
481
538
628
807
1,080
2,469
2,720
2,879
2,821
2,987
2,987
Return on Invested Capital (%)
- -
18.88
12.13
12.97
12.58
16.95
32.43
29.35
18.08
11.56
9.87
4.35
9.5
- -
Return on Capital (%)
- -
19.2
12.03
14.03
13.4
19.21
33.6
30.02
18.15
11.86
9.92
4.4
9.38
- -
Return on Common Equity (%)
- -
19.2
12.03
14.03
13.4
18.11
33
30.05
18.17
11.86
9.93
4.39
9.39
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
- -
- -
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
382
288
382
Market Capitalization
7,105
7,185
8,745

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
2,849
- -
3,012
Cash, Cash Equivalents & STI
1,997
- -
2,220
Accounts Receivable, Net
263
- -
225
Inventories
563
- -
536
Total Current Liabilities
484
- -
579
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
3
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.3%
29.72%
5.87%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
33.62%
12.51%
118.05%
Sales/Revenue/Turnover
23.25%
4.73%
29.77%
Total Cash Common Dividend
- -
- -
-89.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
251
- -
1,209
2024
- -
- -
- -
- -
806
2025
- -
- -
- -
- -
1,046

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
0.14
- -
0.72
2024
- -
- -
- -
- -
0.33
2025
- -
- -
- -
- -
0.71

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.31
2024
- -
- -
- -
- -
0.44
2025
- -
- -
- -
- -
0.05

Company Description

Company Profile APIChatGPT
CEO
Chun Sheng Shi
Full Time Employees
1,078
Sector
Health technology
Industry
Medical specialties
Address
No. 10 Xinmi Xi Er Road Beijing BE China
IPO Date
Dec 30, 2021
Website
clzd.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Beijing Chunlizhengda Medical Instruments Co., Ltd. (688236.SS) engages in the research, development, production, and sales of implantable orthopedic medical devices and related surgical products in China and internationally. Founded in 1998 and headquartered at No. 10, Xinmi West 2nd Road, Tongzhou District, Beijing, China, the company offers a comprehensive portfolio of products including joint prostheses covering hip, knee, shoulder, and elbow replacements; spinal internal fixation systems; sports medicine implants; trauma fixation devices; orthopedic surgical instruments; bone repair materials; platelet-rich plasma (PRP) preparation kits, including China's first fully automatic system; medical centrifuges; dental implants; and knee joint replacement surgical robots. It distributes products through an extensive domestic network across all Chinese provinces, municipalities, and autonomous regions (excluding Hong Kong, Macau, and Taiwan), directly to hospitals, and via overseas distributors on ODM and OEM bases to markets in Asia, South America, Africa, Oceania, and Europe. In recent developments, the company reported a 28% revenue increase to RMB 487.0 million for principal operations in the first half of 2025, alongside expansions in its PRP product matrix with certified active medical centrifuges and ongoing advancements in surgical robotics, including registration certificates for knee joint systems; its shares (also listed as 1858.HK) rose 31% over the last quarter amid projections of 28% annual earnings growth.